07 August 2018
Visiongain’ has launched a new pharma report Global Bioreactors Market 2017-2027:
5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users
The bioreactors market is driven by the increasing use of hybrid technologies, a rise in the rate of adoption of single-use technologies, increasing popularity of single-use bioreactor among biopharmaceutical organizations, and a significant growth in the biologics market. The global bioreactor market is dominated by the single-use bioreactors that hold a major share owing to their high usage in various applications. The main factor driving the increased usage of single-use bioreactors includes low upfront investment cost. There is a high adoption rate of single-use bioreactors owing to reduced capital expenditure costs due to the lower costs of cleaning and sterilizing bioreactors and enhancement of the flexibility in operations during drug manufacturing process.
The lead analyst of the report commented “Asia-Pacific and Rest of the World (RoW) are the emerging bioreactor markets. These regions hold tremendous potential to become the bioreactors market giants in the future. Asia-Pacific countries are estimated to demonstrate tremendous growth for bioreactors owing to the massive expansion of the biopharmaceutical sector in this region.
The rising interest of pharmaceutical organizations to enter the biopharmaceutical market will result in consolidation in the form of strategic alliances between contract manufacturing organizations (CMO’s) and large pharmaceutical/biotechnology organizations. This will result in increased investments and access to cutting-edge manufacturing technologies for CMOs. ”
Leading companies featured in the report include Sartorius AG, Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Danaher Corporation, Eppendorf AG, Applikon Biotechnology Inc., Solaris Biotech, Bioengineering AG, and Infors HT
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to firstname.lastname@example.org or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.
05 September 2019
Somatostatin was used to diagnose gastrointestinal tract tumors and acromegaly in the clinical environment.